Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 684-691

  Emmanouilides, Christos ^a,g   Witzig, Thomas E ^b   Wiseman, Gregory A ^b   Gordon, Leo I ^c   Wang, Hua ^d   Schilder, Russell ^e   Saville, M Wayne ^d   Flinn, Ian ^f   Molina, Arturo ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BIOGEN   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g Interbalkan Medical Centre   (Greece)

Author keywords

Elderly; Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHILL; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELDERLY CARE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OUTPATIENT; PAIN; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RADIOIMMUNOTHERAPY; RASH; RHINITIS; SIDE EFFECT; THROAT IRRITATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOTOXINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 35848954752     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.359     Document Type: Article

References (30)

1. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute, 2006. Online document at: http:// seer.cancer.gov/csr/1975_2003/ Accessed on September 28, 2006.
2. Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43.
3. Balducci L. The geriatric cancer patient: Equal benefit from equal treatment. Cancer Contr 2001;8(2)(Suppl. 1):1.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. The non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780.
5. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(5)(Suppl. 5):75.
6. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375.
7. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hogdkin's lymphoma. J Clin Oncol 2002;20:3262.
8. + B-cell lymphoma: Long-term follow-up of a phase I/II study. Blood 2004;103:4429.
9. Gordon LI, Witzig TE, Molina A, et al. Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymph 2004;5:98.
10. Schilder RJ, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004;19:478.
11. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263.
12. Maartense E, Le Cessie S, Kluin-Nelemans HC, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: Analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 2002;13:1275.
13. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258.
14. Chatta GS, Price TH, Stratton JR, et al. Aging and marrow neutrophil reserves. J Am Geriatr Soc 1994;42:77.
15. Lipschitz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995;22(1)(Suppl. 1):3.
16. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hogdkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352.
17. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530.
18. Tirelli U, Errante D, van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27.
19. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients. Blood 1999;94:33.
20. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694.
21. Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin®) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial [abstract 130]. Blood 2004;104:41a.
22. Hamlin PA, Moskowitz CH, Wegner BC, et al. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90-ibritumomab tiuxetan (Zevalin®) for elderly high-risk patients with untreated DLBCL [abstract 926]. Blood 2005;106:272a.
23. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium-90-ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymph 2006;47:629.
24. Gregory SA, Leonard JP, Vose JM, et al. Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL) [abstract 6561]. J Clin Oncol 2005;23(suppl.):575s.
25. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441.
26. 90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract 2633]. Blood 2004;104:720a.
27. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696.
28. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90-ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3885.
29. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium-90-ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymph 2004;5:202.
30. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I 131 tositumomab for non-Hodgkin's lymphoma. Cancer 2006;106:616.